[Skip to Content]
[Skip to Content Landing]
Views 93
Citations 0
Comment & Response
November 8, 2018

Moving Precision Oncology Forward Amid Myths and Misconceptions—Reply

Author Affiliations
  • 1Oregon Health & Science University School of Medicine, Portland
  • 2Division of Hematology Oncology, Knight Cancer Institute, Oregon Health & Science University, Portland
  • 3Department of Public Health and Preventive Medicine, Oregon Health & Science University, Portland
  • 4Center for Health Care Ethics, Oregon Health & Science University, Portland
JAMA Oncol. Published online November 8, 2018. doi:10.1001/jamaoncol.2018.5111

In Reply We are grateful for the broad interest in our article.1 In our study, we sought to estimate the percentage of US patients with cancer who are eligible for and may benefit from US Food and Drug Administration (FDA)–approved genome-driven cancer therapies, assuming universal testing and access to these therapies. We found that, as of 2018, the percentage of patients eligible for genome-directed therapies was 8.33%, and the percentage of patients benefiting (ie, those whose response may be attributed to the drug) was 4.90%. These percentages increased linearly at approximately 0.5% annually between 2006 and 2018 (as shown in eFigure 1 in the Supplement of our study).1 We emphasized the need to pursue research on genomic treatment alongside broader therapeutic strategies, such as immunotherapy and cytotoxic drugs.

×